An fara gwajin asibiti a Jamhuriyar Demokradiyyar Kongo (DRC) don kimanta tasirin tecovirimat na rigakafin ƙwayar cuta (wanda aka fi sani da TPOXX) a cikin manya da yara masu fama da cutar kyandar biri.Gwajin zai tantance amincin maganin da ikonsa na rage alamun cutar sankarau da kuma hana mummunan sakamako, gami da mutuwa.Karkashin hadin gwiwar gwamnatocin PALM, Cibiyar Kula da Allergy da Cututtuka (NIAID), wani bangare na Cibiyar Kiwon Lafiya ta Kasa, da Cibiyar Nazarin Halittu ta Kasa (INRB) na Jamhuriyar Demokradiyyar Kongo ne ke jagorantar binciken..Hukumomin haɗin gwiwar sun haɗa da Cibiyar Kula da Cututtuka da Cututtuka ta Amurka (CDC), Cibiyar Kula da Magunguna ta Antwerp, Ƙungiyar Ƙungiyoyin Lafiya ta Duniya (ALIMA), da Hukumar Lafiya ta Duniya (WHO).
Kamfanin SIGA Technologies, Inc. (New York) ne ya samar da shi, TPOXX FDA ce ta amince da ƙwayar cuta.Magungunan yana dakatar da yaduwar kwayar cutar a cikin jiki, yana hana sakin kwayoyin cutar kwayar cutar daga kwayoyin jikin.Maganin yana hari akan furotin da aka samu a cikin ƙwayoyin cuta guda biyu da ƙwayar cuta ta biri.
"Cutar biri na haifar da wani gagarumin nauyi na rashin lafiya da mutuwa a tsakanin yara da manya a Jamhuriyar Demokradiyyar Kongo, kuma ana bukatar ingantattun hanyoyin magani cikin gaggawa," in ji Daraktan NIAID Anthony S. Fauci, MD.Amfanin maganin cutar sankarau.Ina so in gode wa abokan aikinmu na kimiyya daga DRC da Kongo don ci gaba da haɗin gwiwarsu don haɓaka wannan muhimmin bincike na asibiti.”
Kwayar cutar kyandar biri ta haifar da bullar cutar lokaci-lokaci da bullar cutar tun cikin shekarun 1970, akasari a yankunan dazuzzukan dazuzzukan Afirka ta Tsakiya da yammacin Afirka.Tun daga watan Mayun 2022, annobar cutar kyandar biri ta ci gaba da yaduwa a wasu yankuna da cutar ba ta bulla ba, ciki har da kasashen Turai da Amurka, inda akasarin wadanda suka kamu da cutar ke faruwa a mazan da suka yi jima'i da maza.Barkewar cutar ta sa Hukumar Lafiya ta Duniya da Ma'aikatar Lafiya da Ayyukan Jama'a ta Amurka kwanan nan ta ayyana dokar ta-baci ta lafiyar jama'a.Daga 1 ga Janairu, 2022 zuwa 5 ga Oktoba, 2022, WHO ta ba da rahoton mutane 68,900 da aka tabbatar sun kamu da cutar tare da mutuwar 25 a kasashe, yankuna da yankuna 106.
A cewar hukumar lafiya ta duniya, cutar da aka gano a matsayin wani bangare na bullar cutar da ake ci gaba da tafkawa a duniya, galibin kwayar cutar kyandar biri ce ta Clade IIb.An kiyasta Clade I yana haifar da cututtuka masu tsanani da kuma yawan mace-mace, musamman a yara, fiye da clade IIa da clade IIb, kuma shine sanadin kamuwa da cuta a Jamhuriyar Demokradiyyar Kongo.Daga ranar 1 ga Janairu, 2022 zuwa 21 ga Satumba, 2022, Cibiyar Kula da Cututtuka ta Afirka (Africa CDC) ta ba da rahoton bullar cutar kyandar biri guda 3,326 (165 da aka tabbatar; 3,161 da ake zargi) da kuma mutuwar mutane 120.
Mutum na iya kamuwa da cutar sankarau ta hanyar cudanya da dabbobi masu kamuwa da cuta kamar rodents, da ba na mutum ba, ko kuma mutane.Ana iya kamuwa da cutar a tsakanin mutane ta hanyar saduwa ta kai tsaye tare da raunukan fata, ruwan jiki da ɗigon iska, gami da kusanci da jima'i, da hulɗar kai tsaye da gurɓataccen tufafi ko kwanciya.Cutar sankarau na iya haifar da alamu kamar mura da raunukan fata masu raɗaɗi.Matsalolin na iya haɗawa da rashin ruwa, kamuwa da ƙwayoyin cuta, ciwon huhu, kumburin ƙwaƙwalwa, sepsis, ciwon ido, da mutuwa.
Gwajin za ta kunshi manya da yara 450 da ke dauke da cutar kyandar biri da dakin gwaje-gwaje ta tabbatar da nauyinta ya kai kilogiram 3.Mata masu ciki ma sun cancanci.Za a ba wa mahalarta masu aikin sa kai ba da gangan don ɗaukar tecovirimat ko placebo capsules a baki sau biyu a rana don kwanaki 14 a kashi wanda ya dogara da nauyin ɗan takara.Binciken ya kasance makafi sau biyu, don haka mahalarta da masu bincike ba su san wanda zai karbi tecovirimat ko placebo ba.
Duk mahalarta zasu kasance a asibiti na akalla kwanaki 14 inda zasu sami kulawar tallafi.Likitoci masu bincike za su sa ido akai-akai game da yanayin asibiti na mahalarta a duk tsawon binciken kuma za su nemi mahalarta su samar da samfuran jini, swabs, da raunukan fata don kimanta dakin gwaje-gwaje.Babban makasudin binciken shine kwatanta ma'anar lokaci zuwa warkar da raunukan fata a cikin marasa lafiya da aka yi wa tecovirimat tare da placebo.Masu binciken za su kuma tattara bayanai kan wasu manufofi na biyu na biyu, ciki har da kwatanta yadda cikin sauri mahalarta suka gwada rashin lafiyar cutar sankarau a cikin jininsu, gabaɗayan tsanani da tsawon lokacin rashin lafiya, da mace-mace tsakanin ƙungiyoyi.
An sallami mahalartan daga asibiti bayan duk raunukan sun kurkure ko kuma sun barke kuma an gwada ba su da kwayar cutar kyandar biri a cikin jininsu tsawon kwanaki biyu a jere.Za a kiyaye su aƙalla kwanaki 28 kuma za a nemi su dawo cikin kwanaki 58 don ziyarar bincike na zaɓi don ƙarin gwaje-gwajen asibiti da na dakin gwaje-gwaje.Wani mai zaman kansa bayanai da kuma kwamitin kula da aminci zai kula da amincin mahalarta a duk tsawon lokacin binciken.
Binciken ya kasance karkashin jagorancin babban jami'in bincike Jean-Jacques Muyembe-Tamfum, Darakta Janar na INRB kuma Farfesa na Microbiology, Faculty of Medicine, Jami'ar Kinshasa, Gombe, Kinshasa;Placid Mbala, MD, Manajan Shirye-shiryen PALM, Shugaban Sashen Cutar Aiki na INRB da Laboratory Genomics.
"Na yi farin ciki cewa cutar kyandar biri ba ta zama cuta da ba a kula da ita ba kuma nan ba da jimawa ba, godiya ga wannan binciken, za mu iya nuna cewa akwai ingantaccen magani ga wannan cuta," in ji Dokta Muyembe-Tamfum.
Don ƙarin bayani, ziyarci Clinicaltrials.gov kuma bincika ID NCT05559099.Jadawalin gwajin zai dogara ne akan adadin rajista.Ana ci gaba da gwajin TPOXX mai goyon bayan NIAID a Amurka.Don bayani game da gwaje-gwajen Amurka, ziyarci gidan yanar gizon rukunin gwaji na Clinical AIDS (ACTG) kuma bincika TPOXX ko nazarin A5418.
PALM gagara ce ga "Pamoja Tulinde Maisha", jumlar Swahili wacce ke nufin "ceton rayuka tare".NIAID ta kafa haɗin gwiwar binciken asibiti na PALM tare da Ma'aikatar Lafiya ta DRC don mayar da martani ga barkewar cutar Ebola ta 2018 a gabashin DRC.Haɗin gwiwar yana ci gaba a matsayin shirin bincike na asibiti da yawa wanda ya ƙunshi NIAID, Sashen Lafiya na DRC, INRB da abokan INRB.Nazarin PALM na farko shine gwajin da aka sarrafa bazuwar jiyya da yawa don cutar cutar Ebola wanda ke goyan bayan amincewar tsari na NIAID-developed mAb114 (Ebanga) da REGN-EB3 (Inmazeb, wanda Regeneron ya haɓaka).
NIAID tana gudanarwa da tallafawa bincike a NIH, Amurka, da ma duniya baki ɗaya don fahimtar abubuwan da ke haifar da cututtuka masu yaduwa da rigakafi da haɓaka ingantattun hanyoyin rigakafi, ganowa, da kuma magance waɗannan cututtuka.Ana samun sanarwar manema labarai, wasiƙun labarai, da sauran abubuwan da suka shafi NIAID akan gidan yanar gizon NIAID.
Game da Cibiyoyin Kiwon Lafiya na Ƙasa (NIH): Cibiyar Kiwon Lafiya ta Ƙasa (NIH) cibiyar bincike ce ta likitancin Amurka na cibiyoyi da cibiyoyi 27 kuma wani ɓangare ne na Ma'aikatar Lafiya da Ayyukan Dan Adam.NIH ita ce hukumar tarayya ta farko wacce ke gudanarwa da tallafawa bincike na likitanci na asali, na asibiti, da na fassara, da binciken musabbabi, jiyya, da jiyya ga cututtukan gama-gari da na yau da kullun.Don ƙarin bayani game da NIH da shirye-shiryenta, ziyarci www.nih.gov.
Lokacin aikawa: Oktoba-14-2022
